Theranos Investor Conference Presentation Deck

Lymphocyte Subset: Method Comparison Study Overview Population Sample type and matrix Comparator Number of miniLabs Study design Analysis Apparently healthy subjects, and <15% adjusted to abnormal levels K2-EDTA venous whole blood BD Multitest 6-color TBNK Reagent with Trucount Tubes on FACSCanto II (BD TBNK) 6 n> 100 subjects (per CLSI EP09-A3) 1 replicate on miniLab, 2 replicates on comparator method Weighted Deming regression analysis and calculate median bias This technology has not been cleared or approved by the FDA and is not for sale in the United States. theranos 43

View entire presentation